Bio-Techne (TECH) Stock Price, News & Analysis

Company Overview

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops and supplies research, diagnostic and bioprocessing products. Its portfolio includes proteins, antibodies, immunoassays, molecular biology reagents, cell and gene therapy tools, and instruments used by academic, pharmaceutical, biotechnology and diagnostic laboratories.

The company operates through brands including R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics. Its products support applications such as protein analysis, spatial biology, single-cell research, biomarker discovery, drug development and the manufacture of cell and gene therapies. Bio-Techne also provides instruments and consumables designed to simplify laboratory workflows and improve the analysis of biological samples.

Founded in 1976 as Research and Diagnostic Systems, the company later became Techne Corporation and adopted the Bio-Techne name in 2014. It serves customers worldwide through direct operations, distributors and international facilities, with products used across research, clinical and biopharmaceutical markets.

Key Stats

• Today's Range: $72.46 to $72.69
• 50-Day Range: $71.23 to $72.48
• 52-Week Range: $43.19 to $72.69
• Volume: 2.37 million shs
• Average Volume: 3.36 million shs
• Market Capitalization: $11.39 billion
• P/E Ratio: 63.16
• Dividend Yield: 0.44%
• Price Target: $68.92
• Consensus Rating: Hold

Bio-Techne Stock Analysis - MarketRank™

Bio-Techne scored higher than 64% of companies evaluated by MarketBeat, and ranked 281st out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Bio-Techne has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on no strong buy ratings, 2 buy ratings, 15 hold ratings, and no sell ratings.

Downside Risk

Bio-Techne has a consensus price target of $68.92, representing about 5.2% downside from its current price of $72.68.

Amount of Analyst Coverage

Bio-Techne has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 13.07%

Earnings Growth

Earnings for Bio-Techne are expected to grow by 13.07% in the coming year, from $1.76 to $1.99 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bio-Techne is 63.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bio-Techne is 63.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.61.

Price to Earnings Growth Ratio

Bio-Techne has a PEG Ratio of 8.61. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bio-Techne has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.81% of the float of Bio-Techne has been sold short.

Short Interest Ratio / Days to Cover

Bio-Techne has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Techne has recently decreased by 8.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Bio-Techne has a dividend yield of 0.44%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bio-Techne does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Bio-Techne is 27.83%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.08% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 1.26

News Sentiment

Bio-Techne has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Bio-Techne this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Techne insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.30% of the stock of Bio-Techne is held by insiders.

Percentage Held by Institutions

98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Record date for 8/28 Dividend: 8/17/2026
• Ex-Dividend for 8/28 Dividend: 8/17/2026
• Record date for 9/4 Dividend: 8/24/2026
• Ex-Dividend for 9/4 Dividend: 8/24/2026
• Dividend Payable: 8/28/2026
• Dividend Payable: 9/04/2026
• Today: 9/22/2026
• AGM 2026: 9/23/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:TECH
• CIK: 842023
• Web: www.bio-techne.com
• Phone: (612) 379-8854
• Fax: 612-656-4400
• Employees: 3,000
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Bio-Techne: $68.92
• High Price Target: $79.00
• Low Price Target: $50.00
• Potential Upside/Downside: -5.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.12
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.15
• Trailing P/E Ratio: 63.19
• Forward P/E Ratio: 41.29
• P/E Growth: 8.61
• Net Income: $181.86 million
• Net Margins: 14.97%
• Pretax Margin: 19.81%
• Return on Equity: 13.23%
• Return on Assets: 10.61%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 4.55
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: $1.22 billion
• Price / Sales: 9.38
• Cash Flow: $2.36 per share
• Price / Cash Flow: 30.83
• Book Value: $13.47 per share
• Price / Book: 5.40

Miscellaneous

• Outstanding Shares: 156,820,000
• Free Float: 154,779,000
• Market Cap: $11.40 billion
• Optionable: Optionable
• Beta: 1.28